Catawba Capital Management VA increased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,040 shares of the biopharmaceutical company’s stock after purchasing an additional 6,635 shares during the quarter. Pfizer makes up about 1.6% of Catawba Capital Management VA’s portfolio, making the stock its 12th largest holding. Catawba Capital Management VA’s holdings in Pfizer were worth $6,820,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Stone House Investment Management LLC increased its position in Pfizer by 0.9% during the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares in the last quarter. Naples Global Advisors LLC increased its position in Pfizer by 0.3% during the 1st quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares in the last quarter. Alpha Windward LLC increased its position in Pfizer by 1.1% during the 1st quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 89 shares in the last quarter. Asset Planning Services Ltd. increased its position in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. Finally, SPC Financial Inc. increased its position in Pfizer by 1.8% during the 1st quarter. SPC Financial Inc. now owns 7,909 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 138 shares in the last quarter. Institutional investors and hedge funds own 69.09% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Shares Bought by Catawba Capital Management VA” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/17/pfizer-inc-pfe-shares-bought-by-catawba-capital-management-va.html.

Pfizer, Inc. (PFE) traded down 1.04% during midday trading on Friday, hitting $35.36. 28,871,059 shares of the stock were exchanged. The stock has a market cap of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00. The company’s 50 day moving average is $33.64 and its 200-day moving average is $33.53. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.84.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.64 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. On average, analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s dividend payout ratio is 94.12%.

A number of equities analysts recently issued reports on the stock. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a research report on Wednesday. BMO Capital Markets reiterated a “buy” rating and set a $37.00 price objective on shares of Pfizer in a research report on Thursday. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Finally, Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $37.72.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares in the company, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 in the last 90 days. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.